<p>Krystal Biotech, Inc. (NASDAQ:KRYS - 获取免费报告) 的股价在周三达到了新的 52 周高点。该股交易最高达到 241.71 美元，最后交易价格为 240.93 美元，成交量为 209368 股。该股此前收盘价为 234.64 美元。</p>
<p>获取 <strong>Krystal Biotech</strong> 警报：</p>
<h2>分析师升级和降级</h2>
<ul>
<li>制药火售：3 只 RSI 显示你不应忽视的股票</li>
</ul>
<p>多家券商最近对 KRYS 进行了评估。Guggenheim 在 10 月 17 日的报告中将 Krystal Biotech 的目标价设定为 224.00 美元，并给予该公司 “买入” 评级。美国银行将 Krystal Biotech 的目标价从 182.00 美元上调至 255.00 美元，并在 10 月 17 日的研究报告中给予该公司 “买入” 评级。Chardan Capital 在 11 月 4 日的研究报告中将 Krystal Biotech 的目标价从 216.00 美元上调至 220.00 美元，并给予该公司 “买入” 评级。HC Wainwright 在 9 月 15 日的研究报告中重申了 “买入” 评级，并对 Krystal Biotech 的目标价为 240.00 美元。最后，花旗集团在 11 月 4 日的报告中将 Krystal Biotech 的目标价从 166.00 美元上调至 198.00 美元，并给予该公司 “中性” 评级。六位投资分析师对该股给予了 “买入” 评级，两位分析师给予了 “持有” 评级。根据 MarketBeat 的数据，该股目前的平均评级为 “适度买入”，平均目标价为 228.14 美元。</p>
<p><strong>阅读我们关于 KRYS 的最新报告</strong></p>
<h2>Krystal Biotech 价格表现</h2>
<ul>
<li>清晰透明：Krystal Biotech 在良好成交量中突破阻力位</li>
</ul>
<p>该股的 50 日移动平均价格为 200.23 美元，200 日移动平均价格为 164.51 美元。该公司的市值为 69.5 亿美元，市盈率为 35.94，贝塔值为 0.48。</p>
<p>Krystal Biotech (NASDAQ:KRYS - 获取免费报告) 最近在 11 月 3 日发布了其财报。该公司报告每股收益（EPS）为 2.66 美元，超出分析师一致预期的 1.12 美元，超出幅度为 1.54 美元。该季度的营业收入为 9780 万美元，而分析师预期为 9372 万美元。Krystal Biotech 的净利润率为 53.30%，股本回报率为 19.36%。整体来看，股票研究分析师预计 Krystal Biotech, Inc.在当前财年将发布 6.14 美元的每股收益。</p>
<h2>Krystal Biotech 的内部买卖</h2>
<p>在相关消息中，内部人士 Suma Krishnan 在 12 月 4 日的交易中出售了 25000 股该股票。该股票以 220.16 美元的平均价格出售，总交易额为 5504000.00 美元。出售完成后，该内部人士在公司持有 1413711 股，价值 311242613.76 美元。这代表其持股比例减少了 1.74%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接获取。公司内部人士持有该公司 13.70% 的股份。</p>
<h2>对 Krystal Biotech 的对冲基金看法</h2>
<p>机构投资者和对冲基金最近增加或减少了在该公司的持股。Brooklyn Investment Group 在第一季度将其在 Krystal Biotech 的持股增加了 291.7%。Brooklyn Investment Group 现在拥有 141 股该公司的股票，价值 25000 美元，此前在该期间购买了 105 股。Hantz Financial Services Inc.在第二季度将其在 Krystal Biotech 的持股增加了 8950.0%。Hantz Financial Services Inc.现在拥有 181 股该公司的股票，价值 25000 美元，此前在上个季度购买了 179 股。Bessemer Group Inc.在第三季度将其在 Krystal Biotech 的持股增加了 106.9%。Bessemer Group Inc.现在拥有 149 股该公司的股票，价值 26000 美元，此前在该期间购买了 77 股。Twin Tree Management LP 在第一季度购买了 Krystal Biotech 的新头寸，价值约 29000 美元。最后，AdvisorNet Financial Inc 在第三季度购买了 Krystal Biotech 的新股份，价值约 30000 美元。目前 86.29% 的股票由机构投资者持有。</p>
<h2>关于 Krystal Biotech</h2>
<p>(获取免费报告)</p>
<p>Krystal Biotech, Inc.是一家商业阶段的生物技术公司，专注于为美国罕见疾病患者发现、开发和商业化基因治疗。它商业化了 VYJUVEK（beremagene geperpavec-svdt，或 B-VEC），用于治疗营养不良性表皮松解症（DEB）。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 Krystal Biotech</li>
<li>上海证券交易所综合指数是什么？</li>
<li>2026 年将主导的三大投资主题</li>
<li>如何计算期权利润</li>
<li>Vertical 的 Valo 发布：伪装成下跌的商业飞跃</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>2026 年的分红股票：市场降温时的投资方向</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Krystal Biotech 吗？</h2>
<p>在你考虑 Krystal Biotech 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Krystal Biotech 并不在名单上。</p>
<p>虽然 Krystal Biotech 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KRYS

<p>Krystal Biotech（纳斯达克代码：KRYS）的股票达到了新的 52 周高点，交易价格最高达到 241.71 美元。分析师对该股票给予了 “适度买入” 的评级，平均目标价格为 228.14 美元。最近的财报超出预期，报告的每股收益为 2.66 美元。内部人士 Suma Krishnan 出售了 25,000 股，机构投资者也调整了他们的持股。该公司专注于针对罕见疾病的基因药物</p>

<p>Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report)'s stock price reached a new 52-week high on Wednesday . The stock traded as high as $241.71 and last traded at $240.93, with a volume of 209368 shares changing hands. The stock had previously closed at $234.64.</p>
<div class="lb-trans"><p>Krystal Biotech, Inc. (NASDAQ:KRYS - 获取免费报告) 的股价在周三达到了新的 52 周高点。该股交易最高达到 241.71 美元，最后交易价格为 240.93 美元，成交量为 209368 股。该股此前收盘价为 234.64 美元。</p>
</div><p>Get <strong>Krystal Biotech</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Krystal Biotech</strong> 警报：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>制药火售：3 只 RSI 显示你不应忽视的股票</li>
</ul>
</div><p>A number of brokerages have recently weighed in on KRYS. Guggenheim set a $224.00 target price on Krystal Biotech and gave the company a &#34;buy&#34; rating in a report on Friday, October 17th. Bank of America boosted their price objective on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, October 17th. Chardan Capital upped their price objective on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 4th. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Monday, September 15th. Finally, Citigroup boosted their price target on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a &#34;neutral&#34; rating in a report on Tuesday, November 4th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $228.14.</p>
<div class="lb-trans"><p>多家券商最近对 KRYS 进行了评估。Guggenheim 在 10 月 17 日的报告中将 Krystal Biotech 的目标价设定为 224.00 美元，并给予该公司 “买入” 评级。美国银行将 Krystal Biotech 的目标价从 182.00 美元上调至 255.00 美元，并在 10 月 17 日的研究报告中给予该公司 “买入” 评级。Chardan Capital 在 11 月 4 日的研究报告中将 Krystal Biotech 的目标价从 216.00 美元上调至 220.00 美元，并给予该公司 “买入” 评级。HC Wainwright 在 9 月 15 日的研究报告中重申了 “买入” 评级，并对 Krystal Biotech 的目标价为 240.00 美元。最后，花旗集团在 11 月 4 日的报告中将 Krystal Biotech 的目标价从 166.00 美元上调至 198.00 美元，并给予该公司 “中性” 评级。六位投资分析师对该股给予了 “买入” 评级，两位分析师给予了 “持有” 评级。根据 MarketBeat 的数据，该股目前的平均评级为 “适度买入”，平均目标价为 228.14 美元。</p>
</div><p><strong>Read Our Latest Report on KRYS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 KRYS 的最新报告</strong></p>
</div><h2>Krystal Biotech Price Performance</h2>
<div class="lb-trans"><h2>Krystal Biotech 价格表现</h2>
</div><ul>
<li>Krystal Clear: Krystal Biotech Clears Resistance in Good Volume</li>
</ul>
<div class="lb-trans"><ul>
<li>清晰透明：Krystal Biotech 在良好成交量中突破阻力位</li>
</ul>
</div><p>The stock's 50 day moving average price is $200.23 and its two-hundred day moving average price is $164.51. The firm has a market capitalization of $6.95 billion, a price-to-earnings ratio of 35.94 and a beta of 0.48.</p>
<div class="lb-trans"><p>该股的 50 日移动平均价格为 200.23 美元，200 日移动平均价格为 164.51 美元。该公司的市值为 69.5 亿美元，市盈率为 35.94，贝塔值为 0.48。</p>
</div><p>Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $1.54. The business had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. As a group, equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Krystal Biotech (NASDAQ:KRYS - 获取免费报告) 最近在 11 月 3 日发布了其财报。该公司报告每股收益（EPS）为 2.66 美元，超出分析师一致预期的 1.12 美元，超出幅度为 1.54 美元。该季度的营业收入为 9780 万美元，而分析师预期为 9372 万美元。Krystal Biotech 的净利润率为 53.30%，股本回报率为 19.36%。整体来看，股票研究分析师预计 Krystal Biotech, Inc.在当前财年将发布 6.14 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Krystal Biotech</h2>
<div class="lb-trans"><h2>Krystal Biotech 的内部买卖</h2>
</div><p>In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This represents a 1.74% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Corporate insiders own 13.70% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Suma Krishnan 在 12 月 4 日的交易中出售了 25000 股该股票。该股票以 220.16 美元的平均价格出售，总交易额为 5504000.00 美元。出售完成后，该内部人士在公司持有 1413711 股，价值 311242613.76 美元。这代表其持股比例减少了 1.74%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接获取。公司内部人士持有该公司 13.70% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Krystal Biotech</h2>
<div class="lb-trans"><h2>对 Krystal Biotech 的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brooklyn Investment Group increased its position in shares of Krystal Biotech by 291.7% during the first quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after purchasing an additional 105 shares during the period. Hantz Financial Services Inc. boosted its stake in Krystal Biotech by 8,950.0% during the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock worth $25,000 after buying an additional 179 shares in the last quarter. Bessemer Group Inc. increased its holdings in Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company's stock valued at $26,000 after buying an additional 77 shares during the period. Twin Tree Management LP bought a new position in shares of Krystal Biotech during the 1st quarter worth about $29,000. Finally, AdvisorNet Financial Inc bought a new stake in Krystal Biotech in the third quarter valued at about $30,000. 86.29% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了在该公司的持股。Brooklyn Investment Group 在第一季度将其在 Krystal Biotech 的持股增加了 291.7%。Brooklyn Investment Group 现在拥有 141 股该公司的股票，价值 25000 美元，此前在该期间购买了 105 股。Hantz Financial Services Inc.在第二季度将其在 Krystal Biotech 的持股增加了 8950.0%。Hantz Financial Services Inc.现在拥有 181 股该公司的股票，价值 25000 美元，此前在上个季度购买了 179 股。Bessemer Group Inc.在第三季度将其在 Krystal Biotech 的持股增加了 106.9%。Bessemer Group Inc.现在拥有 149 股该公司的股票，价值 26000 美元，此前在该期间购买了 77 股。Twin Tree Management LP 在第一季度购买了 Krystal Biotech 的新头寸，价值约 29000 美元。最后，AdvisorNet Financial Inc 在第三季度购买了 Krystal Biotech 的新股份，价值约 30000 美元。目前 86.29% 的股票由机构投资者持有。</p>
</div><h2>About Krystal Biotech</h2>
<div class="lb-trans"><h2>关于 Krystal Biotech</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).</p>
<div class="lb-trans"><p>Krystal Biotech, Inc.是一家商业阶段的生物技术公司，专注于为美国罕见疾病患者发现、开发和商业化基因治疗。它商业化了 VYJUVEK（beremagene geperpavec-svdt，或 B-VEC），用于治疗营养不良性表皮松解症（DEB）。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Krystal Biotech</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>The Top 3 Investment Themes That Will Dominate 2026</li>
<li>How to Calculate Options Profits</li>
<li>Vertical’s Valo Launch: A Commercial Leap Disguised as a Dip</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>Dividend Stocks for 2026: Where to Invest as the Market Cools</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Krystal Biotech</li>
<li>上海证券交易所综合指数是什么？</li>
<li>2026 年将主导的三大投资主题</li>
<li>如何计算期权利润</li>
<li>Vertical 的 Valo 发布：伪装成下跌的商业飞跃</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>2026 年的分红股票：市场降温时的投资方向</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Krystal Biotech Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Krystal Biotech 吗？</h2>
</div><p>Before you consider Krystal Biotech, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Krystal Biotech 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Krystal Biotech 并不在名单上。</p>
</div><p>While Krystal Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Krystal Biotech 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Krystal Biotech（纳斯达克股票代码：KRYS）达到新的 12 个月高点 - 现在仍然是买入的好时机吗？